EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Core Points - EyePoint Pharmaceuticals, Inc. announced the granting of non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan [1] - A total of 44,200 stock options were granted to four new employees, with an exercise price of $12.94 per share, the closing price on May 15, 2024 [2] - The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments [2] Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious retinal diseases [3] - The Company utilizes its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery [3] - The lead product candidate, DURAVYU (EYP-1901), is an investigational treatment for VEGF-mediated retinal diseases [3][4] - Vorolanib, a selective tyrosine kinase inhibitor, is licensed exclusively to EyePoint for ophthalmic diseases outside of certain Asian regions [4]